BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

Leukemia. 2007 Oct;21(10):2204-6. doi: 10.1038/sj.leu.2404772. Epub 2007 May 31.

Authors

L Legros, S Hayette, F E Nicolini, S Raynaud, K Chabane, J-P Magaud, J-P Cassuto, M Michallet

PMID: 17541396
DOI: 10.1038/sj.leu.2404772

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use
Benzamides
Bone Marrow / metabolism
Drug Resistance, Neoplasm / genetics*
Fusion Proteins, bcr-abl / biosynthesis*
Fusion Proteins, bcr-abl / genetics*
Gene Expression Regulation, Leukemic*
Harringtonines / therapeutic use*
Homoharringtonine
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
Male
Middle Aged
Mutation*
Piperazines / pharmacology*
Pyrimidines / pharmacology*
Time Factors
Treatment Outcome

Substances

Antineoplastic Agents
Benzamides
Harringtonines
Piperazines
Pyrimidines
Homoharringtonine
Imatinib Mesylate
Fusion Proteins, bcr-abl